Pier Edoardo Rovatti
Pier Edoardo Rovatti has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Alice S. Mims
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
10 shared publications - Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center, Columbus, OH
10 shared publications - Aristotelis Tsirigos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
10 shared publications - Arwa Shanaah
The Ohio State University 5 Columbus, OH
10 shared publications - Audrey Lasry
New York University 3 New York
10 shared publications - Benjamin Harris Kaffenberger
Department of Dermatology The Ohio State University Wexner Medical Center Columbus Ohio USA
10 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table shows data from targeted mutation panel and WES analysis of myeloid sarcoma patients
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table shows data from targeted mutation panel and WES analysis of myeloid sarcoma patients
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table contains differential expression analysis data from all comparisons shown in the manuscript
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table contains differential expression analysis data from all comparisons shown in the manuscript
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 3 shows cell annotations, malignanat/ME separation and cell type quantifications for scRNA-Seq data shown in figure 4
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 3 shows cell annotations, malignanat/ME separation and cell type quantifications for scRNA-Seq data shown in figure 4
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 4 shows deconvolution of bulk RNA-Seq data and DE analysis on deconvoluted bulk data
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 4 shows deconvolution of bulk RNA-Seq data and DE analysis on deconvoluted bulk data
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary figure 5 shows spatial data from additional myeloid sarcoma samples and niche analysis of spatial data
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary figure 5 shows spatial data from additional myeloid sarcoma samples and niche analysis of spatial data
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table shows scoring of pERK IHC in RAS WT and RAS-mutant bone marrow and myeloid sarcoma
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table shows scoring of pERK IHC in RAS WT and RAS-mutant bone marrow and myeloid sarcoma
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table shows clinical characteristics of patients included in the study
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
This table shows clinical characteristics of patients included in the study
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 2 shows scRNA-Seq data from bone marrow and peripheral blood of myeloid sarcoma patients
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 2 shows scRNA-Seq data from bone marrow and peripheral blood of myeloid sarcoma patients
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 1 shows mutations in the bone marrow of myeloid sarcoma patients and additional examples of clonal evolution
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma
Supplementary Figure 1 shows mutations in the bone marrow of myeloid sarcoma patients and additional examples of clonal evolution
- 20 May 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 759-773
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma
Myeloid sarcoma, an aggressive extramedullary subtype of acute myeloid leukemia (AML), occurs in approximately 20% of patients, and remains strikingly understudied in large-scale genomic and multiomic investigations. The key drivers of its tumor evolution are largely unknown, timely detection in asymptomatic patients poses a clinical challenge, and effective treatment options are limited as patients are often excluded from clinical trials, rendering it a largely neglected disease entity. Here, we demonstrate that myeloid sarcoma evolves from medullary AML but exhibits distinct site-specific clonal evolution. This is supported by unique transcriptional signatures of myeloid sarcoma, reflecting adaptation to the extramedullary microenvironment. We establish a proof of concept that circulating tumor DNA sequencing captures the molecular composition of myeloid sarcoma, offering a potential non-invasive approach for molecular profiling of extramedullary AML. Our findings highlight marked differences between medullary AML and myeloid sarcoma, including universal molecular evolution and RAS pathway activation as disease hallmarks.
- 20 May 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (5) , 759-773
RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma
Myeloid sarcoma, an aggressive extramedullary subtype of acute myeloid leukemia (AML), occurs in approximately 20% of patients, and remains strikingly understudied in large-scale genomic and multiomic investigations. The key drivers of its tumor evolution are largely unknown, timely detection in asymptomatic patients poses a clinical challenge, and effective treatment options are limited as patients are often excluded from clinical trials, rendering it a largely neglected disease entity. Here, we demonstrate that myeloid sarcoma evolves from medullary AML but exhibits distinct site-specific clonal evolution. This is supported by unique transcriptional signatures of myeloid sarcoma, reflecting adaptation to the extramedullary microenvironment. We establish a proof of concept that circulating tumor DNA sequencing captures the molecular composition of myeloid sarcoma, offering a potential non-invasive approach for molecular profiling of extramedullary AML. Our findings highlight marked differences between medullary AML and myeloid sarcoma, including universal molecular evolution and RAS pathway activation as disease hallmarks.